Currently, CA125 and HE4 remain the only FDA-approved biomarkers for epithelial ovarian cancer (EOC), yet their limited sensitivity-particularly in early-stage disease-highlights the need for improved diagnostic tools. This evidence concerns the gene WFDC2 and ovarian carcinoma.